中国医药科学
中國醫藥科學
중국의약과학
CHINA MEDICINE AND PHARMACY
2015年
13期
76-78
,共3页
马来酸曲美布丁%布拉氏酵母菌%肠易激惹综合征
馬來痠麯美佈丁%佈拉氏酵母菌%腸易激惹綜閤徵
마래산곡미포정%포랍씨효모균%장역격야종합정
Trimebutine maleate%Saccharomyces boulardii%Irritable bowel syndrome
目的：探讨马来酸曲美布丁联合布拉氏酵母菌治疗腹泻型肠易激惹综合征的临床疗效及安全性。方法收集2010年6月~2013年8月期间在本院消化科就诊的DIBS患者114例，随机分为联合组和对照组，每组67例。对照组采用马来酸曲美布丁治疗，联合组在对照组基础上加用布拉氏酵母菌治疗，比较两组腹泻、腹痛症状评分及临床症状总积分，同时观察临床疗效及不良反应发生情况。结果联合组显效率、总有效率分别为52.2%、91.0%，对照组分别为34.3%、74.6%，联合组显效率、总有效率明显高于对照组（ P＜0.05）。联合组治疗后腹痛、腹泻评分及临床症状总积分分别为（1.8±0.2）分、（1.8±0.2）分、（3.6±0.5）分，对照组（1.5±0.3）分、（1.3±0.2）分、（2.8±0.3）分，联合组治疗后腹痛、腹泻评分及临床症状总积分明显高于对照组（P＜0.05）。联合组、对照组不良反应发生率分别为13.4%、14.9%，两组不良反应发生率无明显差异（P＞0.05）。结论马来酸曲美布丁联合布拉氏酵母菌治疗DIBS具有协同增效作用，能更有效的改善患者的临床症状，提高临床疗效，且安全可靠，值得临床推广应用。
目的：探討馬來痠麯美佈丁聯閤佈拉氏酵母菌治療腹瀉型腸易激惹綜閤徵的臨床療效及安全性。方法收集2010年6月~2013年8月期間在本院消化科就診的DIBS患者114例，隨機分為聯閤組和對照組，每組67例。對照組採用馬來痠麯美佈丁治療，聯閤組在對照組基礎上加用佈拉氏酵母菌治療，比較兩組腹瀉、腹痛癥狀評分及臨床癥狀總積分，同時觀察臨床療效及不良反應髮生情況。結果聯閤組顯效率、總有效率分彆為52.2%、91.0%，對照組分彆為34.3%、74.6%，聯閤組顯效率、總有效率明顯高于對照組（ P＜0.05）。聯閤組治療後腹痛、腹瀉評分及臨床癥狀總積分分彆為（1.8±0.2）分、（1.8±0.2）分、（3.6±0.5）分，對照組（1.5±0.3）分、（1.3±0.2）分、（2.8±0.3）分，聯閤組治療後腹痛、腹瀉評分及臨床癥狀總積分明顯高于對照組（P＜0.05）。聯閤組、對照組不良反應髮生率分彆為13.4%、14.9%，兩組不良反應髮生率無明顯差異（P＞0.05）。結論馬來痠麯美佈丁聯閤佈拉氏酵母菌治療DIBS具有協同增效作用，能更有效的改善患者的臨床癥狀，提高臨床療效，且安全可靠，值得臨床推廣應用。
목적：탐토마래산곡미포정연합포랍씨효모균치료복사형장역격야종합정적림상료효급안전성。방법수집2010년6월~2013년8월기간재본원소화과취진적DIBS환자114례，수궤분위연합조화대조조，매조67례。대조조채용마래산곡미포정치료，연합조재대조조기출상가용포랍씨효모균치료，비교량조복사、복통증상평분급림상증상총적분，동시관찰림상료효급불량반응발생정황。결과연합조현효솔、총유효솔분별위52.2%、91.0%，대조조분별위34.3%、74.6%，연합조현효솔、총유효솔명현고우대조조（ P＜0.05）。연합조치료후복통、복사평분급림상증상총적분분별위（1.8±0.2）분、（1.8±0.2）분、（3.6±0.5）분，대조조（1.5±0.3）분、（1.3±0.2）분、（2.8±0.3）분，연합조치료후복통、복사평분급림상증상총적분명현고우대조조（P＜0.05）。연합조、대조조불량반응발생솔분별위13.4%、14.9%，량조불량반응발생솔무명현차이（P＞0.05）。결론마래산곡미포정연합포랍씨효모균치료DIBS구유협동증효작용，능경유효적개선환자적림상증상，제고림상료효，차안전가고，치득림상추엄응용。
Objective To investigate the clinical effect and safety of treating diarrhea irritable bowel syndrome(DIBS) by trimebutine maleate and saccharomyces boulardii.Methods 114 patients with DIBS who were treated in digestive department of our hospital from Jun, 2010 to Aug,2013, They were randomly divided into combination group and control group. There were 67 patients in each group. Control group were treated by trimebutine maleate, combination group were treated saccharomyces boulardii on basic of control group,the symptoms score of diarrhea, abdominal pain symptoms, and total clinical symptom integral were compared between two group.At the same time, the clinical effect and adverse reaction were observed.Results The excellence rate and total effective rate in combination group were respectively 52.2%, 91.0%, those in control group were respectively 34.3%, 74.6%, the excellence rate and total effective rate in combination group were obviously higher than those in control group (P<0.05), the symptoms score of diarrhea, abdominal pain and total clinical symptom integral in combination group were respectively (1.8±0.2) score, (1.8±0.2)score, (3.6±0.5) score after treatment.those in control group were respectively(1.5±0.3) score,(1.3±0.2) score,(2.8±0.3)score. The symptoms score of diarrhea, abdominal pain and total clinical symptom integral of combination group were obviously higher than those in control group(P<0.05).The incidence of adverse reaction in combination group and control group were respectively 13.4%, 14.9%, the incidence of adverse reaction between two groups had no significant difference (P>0.05).ConclusionThere are synergistic effect in treating DIBS by trimebutine maleate and saccharomyces boulardii. It can more effectively improve patient's clinical symptoms, improve clinical efficacy and it is safe and reliable,so it is well worthy of popularizing.
